CYSLTR1 and Alzheimer disease: These responses are inhibited by Lukast drugs (pranlukast, montelukast, and zafirlukast), suggesting that CysLTR1 is a pro-inflammatory regulator and is involved in AD initiation and progression [66,84,105,106].